Please wait, loading...
The revocation of Jersey Hemp's cultivation, extraction and export licences by the Government of Jersey (at the behest of the UK Government) is unfortunate for all those involved in the business, but it is no surprise – it was inevitable.
Steve Oliver Co-Founder at The Canna Consultants discussing Medicinal Cannabis at Malta Med-Tech | November 2022
This week alerted the wider CBD market to some old issues which we had been repeatedly raising with participants who were either already subscribed to the EIHA application or were the recipients of invitations to join the application, plus a considerable new issue around the EIHA Toxicology Consortium results.
For many, many months now we at The Canna Consultants have we have repeatedly informed market participants that those who had subscribed to the EIHA Toxicology Consortium were going to get a Rude Awakening...
Recreational drug use has been categorised as immoral, evil and a fundamental characteristic of weakness by both the press and many social commentators over the past 50 years. This has provided the continued justification for punitive enforcement and the “Outraged from…” style of journalism which...
With Canada and the US leading the way, Europe is looking at its growing cannabis market with excitement, but there are plenty of mistakes to be avoided.
Over the last few months we have read with increasing frequency posts and publications by the Secretariat to the APPG, the Advisory Board to the Secretariat (SAB APPG) and by the members to the Secretariat Advisory Board. Interestingly we have neither heard nor read anything by the actual All Party Parliamentary Group on CBD Products (APPG).
Reaction to the EFSA statement on safety of cannabidiol has been mixed. Some claiming it as an opportunity, others citing calamity and the usual suspects claiming to have foreseen it – no-one foresaw this.
HEADLINES FROM EFSA’s STATEMENT ON THE “SAFETY OF CANNABIDIOL AS A NOVEL FOOD: DATA GAPS AND UNCERTAINTIES” (PUBLISHED ON 7TH JUNE 2022)
NORTH AMERICAN UPDATE HEXO & TILRAY A month ago we observed the following: Hexo is probably in the worst position of all three. They aren’t profitable, will never be profitable, and owe lots of money that’s coming due. Buying Zenabis and 48 North, neither of which made any strategic sense, given how poorly those businesses...